Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, November 18, 2026

CASS4 Gene Directs Microglia to Contain Alzheimer’s Plaques

 Does your competent? doctor and hospital have enough brains to ensure further research occurs?

You need this because of all this.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:


CASS4 Gene Directs Microglia to Contain Alzheimer’s Plaques

Summary:

Neuroscientists at the University of Virginia School of Medicine have uncovered the elusive biological mechanism of CASS4, a prominent genetic risk factor for Alzheimer’s disease. In a study published in the Journal of Experimental Medicine, researchers led by Dr. John Lukens demonstrated that CASS4 acts not within neurons as previously assumed, but directly within microglia, the brain’s resident immune cells.

The gene functions as a master regulator enabling microglia to surround, contain, and tightly compact toxic amyloid-beta plaques into manageable clusters. When CASS4 activity is impaired, microglia fail to envelop plaques, allowing neurotoxic proteins to spread unrestrained, triggering synaptic destruction, neuronal death, and rapid cognitive decline.

Key Facts:

  • Paradigm Shift to Glial Immunity: While earlier hypotheses assumed the CASS4 risk gene operated inside neurons, UVA Health researchers proved it functions predominantly inside microglia to direct immune surveillance and plaque compaction.
  • Loss of Plaque Barrier Defense: Disruption of CASS4 leaves microglia incapable of effectively corralling amyloid-beta deposits; uncompacted plaques expand rapidly, accelerating local neurotoxicity and cognitive deterioration in preclinical models.
  • Therapeutic and Diagnostic Potential: Defective CASS4 signaling may serve as an early diagnostic biomarker for Alzheimer’s risk, while therapies that enhance or restore its function offer an untapped immunotherapeutic avenue across neurodegenerative diseases.

Source: University of Virginia / Journal of Experimental Medicine

More than six million Americans live with Alzheimer’s disease, a progressive neurodegenerative disorder that erodes memory, executive function, and personal identity. Ranked as the sixth leading cause of death in the United States, Alzheimer’s is characterized pathologically by two hallmark protein aggregations: extracellular amyloid-beta plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau.

Large-scale genome-wide association studies (GWAS) have repeatedly flagged CASS4 (Cas Scaffold Protein Family Member 4) as a significant genetic risk locus for late-onset Alzheimer’s disease. However, despite its consistent link to dementia risk, its molecular function and cellular site of action inside the brain remained unknown.

Now, a research team at the University of Virginia School of Medicine led by Dr. John Lukens has resolved this question.

Publishing in the Journal of Experimental Medicine, the investigators reveal that CASS4 operates as a critical genetic coordinator of microglia, the central nervous system’s specialized immune scavengers. Rather than serving an intrinsic neuronal role, CASS4 orchestrates the microglial machinery required to corral and compact neurotoxic debris, preventing widespread collateral damage to neighboring circuits.

Microglia as the Brain’s Garbage Disposal

Under healthy physiological conditions, microglia constantly survey brain parenchyma with motile branches. When toxic amyloid-beta monomers oligomerize into fibrillar deposits, healthy microglia migrate toward the site, forming a dense protective barrier around the plaque core.

This microglial wall physically isolates the toxic fibrils and mechanically compacts them into dense, tightly packaged bundles, preventing neurotoxic oligomers from diffusing outward and poisoning adjacent neuronal synapses.

When Lukens’ team disrupted CASS4 function in preclinical models, this defense collapsed:

  • Impaired Plaque Compaction: Microglia lost their targeted chemotactic response to nascent plaques, failing to form cohesive protective barriers around amyloid aggregates.
  • Accelerated Plaque Expansion: Without compaction, amyloid-beta grew rapidly in diffuse, unregulated geometries, exposing wider swaths of surrounding brain tissue to toxic oligomers.
  • Synaptic Damage and Cognitive Decline: The unchecked spread of uncompacted plaques triggered downstream neuronal dysfunction, dendritic loss, and accelerated cognitive impairment.

“These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer’s disease,” said Dr. Lukens, director of UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases. “Our work further suggests that defective CASS4 activity may serve as an early-onset biomarker to detect Alzheimer’s and that therapeutic strategies which boost its function may offer a much-needed approach to treat this devastating brain disease.”

Shifting the Therapeutic Paradigm

Historically, neurodegenerative drug development focused heavily on targeting neurons directly or attempting to chemically dissolve amyloid aggregates after they formed. The UVA team’s findings provide evidence for neuroimmunological modulation as an alternative strategy.

“Despite CASS4 being an Alzheimer’s risk gene, really nothing is known about what this gene does or how it affects the brain during disease. Our lab sought to address this major knowledge gap with this paper,” explained lead author Addie Walsh, a UVA physiology graduate student who conducted the foundational experiments before heading to Novartis’ Neurodegeneration Team to continue microglial research. “These are important findings because they give us new insight into how this understudied AD risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology.”

The researchers demonstrated that the loss of CASS4 causes broad downstream dysregulation of microglial transcriptional networks, influencing cellular clearance mechanisms relevant to multiple protein-misfolding disorders.

“Many in the field initially presumed that CASS4 was likely functioning in neurons to influence Alzheimer’s. Our findings shift this paradigm by proving that CASS4 predominantly acts through the immune system,” Lukens noted. “This is particularly exciting, as it has only been in recent years that immune-targeting strategies have been considered for the treatment of neurodegenerative diseases, and this remains an untapped therapeutic avenue with tremendous potential.”

Translational Opportunities at the Manning Institute

Lukens’ laboratory, affiliated with both the Harrison Family Translational Research Center and UVA’s Center for Brain Immunology and Glia (BIG Center), is now leveraging resources within the newly launched Paul and Diane Manning Institute of Biotechnology. The institute is specifically engineered to translate foundational biomedical discoveries into clinically actionable therapeutics.

The investigators are working to screen small-molecule agonists and gene-therapy vectors capable of upregulating CASS4 expression or mimicking its scaffolding activity within human microglia.

By restoring the brain’s endogenous capacity to compact and neutralize metabolic toxins, future immunotherapies targeting the CASS4 pathway could offer a targeted strategy to halt Alzheimer’s progression before extensive neuronal loss occurs.

Questions and Answers

What is the CASS4 gene, and how does it relate to Alzheimer’s disease?

CASS4 is a genetic risk factor repeatedly identified in genome-wide association studies for Alzheimer’s disease. This study reveals that CASS4 directs microglia to act as the brain’s “trash compactors,” forming protective physical barriers around toxic amyloid-beta plaques to minimize neurotoxic exposure.

What happens to the brain when CASS4 function is disrupted?

When CASS4 is inactive or impaired, microglia fail to surround and compress amyloid-beta plaques. As a result, the plaques grow faster, spread more aggressively into surrounding tissue, damage nearby neurons, and accelerate memory loss and cognitive decline.

Why does this study change how scientists view Alzheimer’s treatments?

Most previous research assumed CASS4 operated within neurons. Proving that it acts through microglia confirms that immune dysfunction is central to Alzheimer’s pathology, opening opportunities for therapies designed to boost microglial clearance rather than solely targeting neuronal pathways.

Editorial Notes:

  • This article was edited by a Neuroscience News editor.
  • Journal paper reviewed in full.
  • Additional context added by our staff.

  • Media Contact: Josh Barney
  • Source: University of Virginia
  • Image Credit: Image credited to Neuroscience News
  • Original Research is Open Access: Journal of Experimental Medicine (Oct 1, 2026). “Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis.” Authors: Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills, III, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo, and John R. Lukens.
  • DOI: 10.1084/jem.20260104

No comments:

Post a Comment